Literature DB >> 25762124

The evolving role of cytotoxic chemotherapy in the management of patients with metastatic prostate cancer.

Elan Diamond1, María del Carmen Garcias, Beerinder Karir, Scott T Tagawa.   

Abstract

Prostate cancer (PC) is the most common cancer in men in the United States. Although outcomes are excellent for early-stage disease, survival for men with metastatic PC is limited. While older studies did not supported the use of chemotherapy in PC, the efficacy of taxane chemotherapy plus prednisone is now well established in men with metastatic castration resistant PC (CRPC). The results of CHAARTED trial have further expanded the use of chemotherapy to patients with metastatic hormone-sensitive disease. The clinical efficacy of taxanes over other chemotherapeutics may be a result of its ability to inhibit microtubule-dependent trafficking of proteins such as the androgen-receptor (AR). Ongoing research uses chemotherapy earlier in the disease course as well as explores the utility of combining cytotoxic chemotherapy with biologic agents.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25762124     DOI： 10.1007/s11864-014-0324-2

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN： 1534-6277


  74 in total

1.  2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

Authors:  Thomas J Smith; James Khatcheressian; Gary H Lyman; Howard Ozer; James O Armitage; Lodovico Balducci; Charles L Bennett; Scott B Cantor; Jeffrey Crawford; Scott J Cross; George Demetri; Christopher E Desch; Philip A Pizzo; Charles A Schiffer; Lee Schwartzberg; Mark R Somerfield; George Somlo; James C Wade; James L Wade; Rodger J Winn; Antoinette J Wozniak; Antonio C Wolff
Journal:  J Clin Oncol       Date:  2006-05-08       Impact factor: 44.544

2.  Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer.

Authors:  T M Beer; W C Pierce; B A Lowe; W D Henner
Journal:  Ann Oncol       Date:  2001-09       Impact factor: 32.976

3.  Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer.

Authors:  Matthew D Galsky; Eric J Small; William K Oh; Isan Chen; David C Smith; A Dimitrios Colevas; Lou Martone; Tracy Curley; Anthony Delacruz; Howard I Scher; W Kevin Kelly
Journal:  J Clin Oncol       Date:  2005-03-01       Impact factor: 44.544

4.  Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial.

Authors:  A Fléchon; D Pouessel; C Ferlay; D Perol; P Beuzeboc; G Gravis; F Joly; S Oudard; G Deplanque; S Zanetta; P Fargeot; F Priou; J P Droz; S Culine
Journal:  Ann Oncol       Date:  2011-03-24       Impact factor: 32.976

5.  Extrapulmonary small cell carcinoma.

Authors:  E Galanis; S Frytak; R V Lloyd
Journal:  Cancer       Date:  1997-05-01       Impact factor: 6.860

6.  A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813.

Authors:  William K Oh; Susan Halabi; W Kevin Kelly; Cary Werner; Paul A Godley; Nicholas J Vogelzang; Eric J Small
Journal:  Cancer       Date:  2003-12-15       Impact factor: 6.860

7.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

8.  Molecular determinants of resistance to antiandrogen therapy.

Authors:  Charlie D Chen; Derek S Welsbie; Chris Tran; Sung Hee Baek; Randy Chen; Robert Vessella; Michael G Rosenfeld; Charles L Sawyers
Journal:  Nat Med       Date:  2003-12-21       Impact factor: 53.440

9.  Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers.

Authors:  Stéphane Culine; Mounira El Demery; Pierre-Jean Lamy; François Iborra; Christophe Avancès; Frédéric Pinguet
Journal:  J Urol       Date:  2007-07-16       Impact factor: 7.450

10.  Small cell anaplastic carcinoma of the prostate: a clinical, pathological and immunohistological study of 27 patients.

Authors:  J E Oesterling; C G Hauzeur; G M Farrow
Journal:  J Urol       Date:  1992-03       Impact factor: 7.450
View more
  2 in total

1.  Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer.

Authors:  Emmanuel S Antonarakis; Scott T Tagawa; Giuseppe Galletti; Daniel Worroll; Karla Ballman; Marie Vanhuyse; Guru Sonpavde; Scott North; Costantine Albany; Che-Kai Tsao; John Stewart; Atef Zaher; Ted Szatrowski; Wei Zhou; Ada Gjyrezi; Shinsuke Tasaki; Luigi Portella; Yang Bai; Timothy B Lannin; Shalu Suri; Conor N Gruber; Erica D Pratt; Brian J Kirby; Mario A Eisenberger; David M Nanus; Fred Saad; Paraskevi Giannakakou
Journal:  J Clin Oncol       Date:  2017-06-20       Impact factor: 44.544

2.  LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating Cancer Therapeutics.

Authors:  Holly M Nguyen; Robert L Vessella; Colm Morrissey; Lisha G Brown; Ilsa M Coleman; Celestia S Higano; Elahe A Mostaghel; Xiaotun Zhang; Lawrence D True; Hung-Ming Lam; Martine Roudier; Paul H Lange; Peter S Nelson; Eva Corey
Journal:  Prostate       Date:  2017-02-03       Impact factor: 4.104
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.